Suresh K. Durgam - Mar 10, 2023 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
EVP, Chief Medical Officer
Signature
s/ Lawrence J. Hineline, Attorney-in-fact
Stock symbol
ITCI
Transactions as of
Mar 10, 2023
Transactions value $
-$330,794
Form type
4
Date filed
3/13/2023, 07:36 PM
Previous filing
Mar 8, 2023
Next filing
Jul 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise +7.34K +31.79% 30.4K Mar 10, 2023 Direct F1
transaction ITCI Common Stock Sale -$315K -7K -22.98% $45.08 23.5K Mar 13, 2023 Direct F2, F3
transaction ITCI Common Stock Sale -$15.3K -346 -1.48% $44.29 23.1K Mar 13, 2023 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Restricted Stock Units Options Exercise $0 -7.34K -33.33% $0.00 14.7K Mar 10, 2023 Common Stock 7.34K Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.63 to $45.4227, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.82 to $44.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 Each restricted stock unit represents a contingent right to receive one share of common stock.
F6 On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.